Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECORDS sepsis corticosteroid response trial
2020-000296-21Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sepsis comparing Hydrocortisone + fludrocortisone with Placebo (2 arms). Primary endpoint: Composite of death or persistent organ dysfunction. Started Mar 2020; status: active.
02
Drugs
hydrocortisonefludrocortisone
03
Conditions
sepsis
Beyond the preview
Go deeper on 2020-000296-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000296-21.